Association Between Antecedent Statin Use and Decreased Mortality in Hospitalized Patients with COVID-19
Authors:
Preprint
- 11 August 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections and ARDS, but their benefit has not been assessed in COVID-19. Thus, we sought to determine whether antecedent statin use is associated with lower in-hospital mortality in patients hospitalized for COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1st through May 12th, 2020 with study period ending on June 11th, 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline socio-demographic and clinical characteristics, and outpatient medications. The primary endpoint included in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, demographic, baseline, and outpatient medication information were well balanced. Statin use was significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.48, 95% CI 0.36 – 0.64, p<0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 was associated with lower inpatient mortality. Randomized clinical trials evaluating the utility of statin therapy in patients with COVID-19 are needed.Keywords
All Related Versions
This publication has 45 references indexed in Scilit:
- Autopsy Findings and Venous Thromboembolism in Patients With COVID-19Annals of Internal Medicine, 2020
- Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future ResearchThrombosis and Haemostasis, 2020
- Endothelial cell infection and endotheliitis in COVID-19The Lancet, 2020
- Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin TherapyCirculation: Cardiovascular Imaging, 2017
- The Important Role of Lipid Raft-Mediated Attachment in the Infection of Cultured Cells by Coronavirus Infectious Bronchitis Virus Beaudette StrainPLOS ONE, 2017
- Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-κB signaling in PMA-stimulated THP-1 monocytesBiomedicine & Pharmacotherapy, 2016
- Effect of Two Intensive Statin Regimens on Progression of Coronary DiseaseNew England Journal of Medicine, 2011
- Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome*Critical Care Medicine, 2011
- Inflammation in AtherosclerosisJACC, 2009
- Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy VolunteersAmerican Journal of Respiratory and Critical Care Medicine, 2009